Thus, there is an important clinical need to identify biomarkers for these promising therapies.3, 4 Related to this, while higher PD‐1 and PD‐L1 expressions in primary tumors have shown to predict poor survival,5, 6, 7 their role in selecting patients for immune checkpoint inhibitors remains unclear.8, 9, 10 Of particular interest, many studies evaluating these biomarkers have focused on the expression in the primary ccRCC tumor, vs the metastatic tumor that is more therapeutically relevant. Here, CD274 is linked to neoplasm.